Combating multi-
drug resistant
bacterial infections should be a universal urgency. The gram- positive Staphylococcus aureus (S. aureus) bacteria are generally harmless; healthy people frequently have them on their skin and nose. These bacteria, for the most part, produce no difficulties or only minor
skin diseases.
Antibiotics and cleansing of the affected region are usually the treatments of choice. S. aureus can become virulent causing serious
infections that may lead to pustules to
sepsis or death. Normally, it is thought that
antibiotics may solve problems concerning
bacterial infection; but unfortunately, Staphylococci have evolved mechanisms to resist drugs. Methicillin-Resistant Staphylococcus aureus (MRSA); both in hospitals and in the community,
infections are evolving into dangerous pathogens. Health care practitioners may need to use
antibiotics with more adverse effects to treat
antibiotic-resistant S. aureus
infections. Amid existing efforts to resolve this problem,
phage therapy proposes a hopeful alternate to face
Staphylococcal infections. When the majority of
antibiotics have failed to treat
infections caused by multidrug-resistant bacteria, such as
methicillin- and
vancomycin-resistant S. aureus,
phage therapy may be an option. Here, we appraise the potential efficacy, current knowledge on bacteriophages for S. aureus, experimental research and information on their clinical application, and limitations of
phage therapy for S. aureus
infections.